Compare Amphastar Pharmaceuticals Inc (AMPH) vs Bank of Montreal (BMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Bank of Montreal — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Bank of Montreal trades at $181.45 (market cap $127.25B). The key difference: Bank of Montreal is far larger — about 147.3× Amphastar Pharmaceuticals Inc's market cap, and Bank of Montreal pays a 2.68% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BMO | |
|---|---|---|
Market Cap | $863.95M | $127.25B |
Sector | Health | Financials |
52-Week High | $30.81 | $183.65 |
52-Week Low | $16.87 | $112.54 |
Enterprise Value | $1.26B | — |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
BMO trades at $181.55, up 0.4% with a bullish technical signal. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $2.66. Recent strategic moves include the $1.44 billion sale of Moneris and the acquisition of Euroz Hartleys' Australian capital markets business, strengthening its global metals and mining franchise. The stock shows strong fundamental performance with 25.92% net income margin and 11.05% ROE.
BMO presents a balanced investment case with solid earnings momentum and strategic expansion, though trading near resistance at $182. Key opportunities include consistent dividend payments and global banking recognition, while risks involve interest rate sensitivity and competitive pressures in the North American banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →
